Changshan Biochemical Pharma signed a $9.5 million deal to commercialize an osteoarthritis treatment in China developed by Israel’s Kitov Pharma. Changshan will have exclusive rights to import, manufacture and distribute Consensi™ in greater China. A combination drug, Consensi consists of two FDA-approved drugs: Celebrex®, a non-steroidal anti-inflammatory COX-2 inhibitor for osteoarthritis pain, and Norvasc®, a calcium channel blocker that lowers blood pressure, which is often a side effect of osteoarthritis drugs.
Source: China Biotoday
